DDInter781 DDInter228
Fosinopril is a phosphinic acid-containing ester prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly hydrolyzed to fosinoprilat, its principle active metabolite. Fosinoprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Fosinopril may be used to treat mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.
Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post-treatment. The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy. Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens. Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission. The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen compared to the previous standard of care. Importantly, bleomycin - a highly toxic agent - was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease.
Fosinopril {u} (Compound) resembles {v} (Compound) Enalapril
Enalapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Fosinopril {u} (Compound) resembles {v} (Compound) Enalapril
Enalapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naltrexone
Naltrexone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Fosinopril {u} (Compound) resembles {v} (Compound) Lisinopril
Lisinopril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naltrexone
Naltrexone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Fosinopril {u} (Compound) resembles {v} (Compound) Spirapril
Spirapril {u} (Compound) resembles {v} (Compound) Nateglinide
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Fosinopril {u} (Compound) resembles {v} (Compound) Ramipril
Ramipril {u} (Compound) resembles {v} (Compound) Moexipril
Moexipril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Fosinopril {u} (Compound) resembles {v} (Compound) Spirapril
Spirapril {u} (Compound) resembles {v} (Compound) Quinapril
Quinapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Fosinopril {u} (Compound) resembles {v} (Compound) Enalapril
Enalapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canagliflozin
Canagliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Fosinopril {u} (Compound) resembles {v} (Compound) Mitiglinide
Mitiglinide {u} (Compound) resembles {v} (Compound) Trandolapril
Trandolapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Fosinopril {u} (Compound) treats {v} (Disease) hypertension
hypertension {u} (Disease) is treated by {v} (Compound) Verapamil
Verapamil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Fosinopril {u} (Compound) binds {v} (Gene) SLC15A1
SLC15A1 {u} (Gene) is bound by {v} (Compound) Valganciclovir
Valganciclovir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Fosinopril (Compound) resembles Enalapril (Compound) and Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Fosinopril (Compound) resembles Enalapril (Compound) and Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Fosinopril (Compound) resembles Lisinopril (Compound) and Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Fosinopril (Compound) resembles Spirapril (Compound) and Spirapril (Compound) resembles Nateglinide (Compound) and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Fosinopril (Compound) resembles Ramipril (Compound) and Ramipril (Compound) resembles Moexipril (Compound) and Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Fosinopril (Compound) resembles Spirapril (Compound) and Spirapril (Compound) resembles Quinapril (Compound) and Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Fosinopril (Compound) resembles Enalapril (Compound) and Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Fosinopril (Compound) resembles Mitiglinide (Compound) and Mitiglinide (Compound) resembles Trandolapril (Compound) and Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Fosinopril (Compound) treats hypertension (Disease) and hypertension (Disease) is treated by Verapamil (Compound) and Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Fosinopril (Compound) binds SLC15A1 (Gene) and SLC15A1 (Gene) is bound by Valganciclovir (Compound) and Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin